Predictive value of phosphorylated mammalian target of rapamycin for disease‑free survival in breast cancer patients receiving neoadjuvant chemotherapy

Wang,Shuo; Sun,Yiqun; He,Anning; Zheng,Caiwei; Zheng,Xinyu

doi:10.3892/ol.2014.2551

Predictive value of phosphorylated mammalian target of rapamycin for disease‑free survival in breast cancer patients receiving neoadjuvant chemotherapy

Authors:
- Shuo Wang
- Yiqun Sun
- Anning He
- Caiwei Zheng
- Xinyu Zheng
View Affiliations

Affiliations: Department of Breast Surgery, First Affiliated Hospital, China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Burns, General Hospital of Benxi Iron and Steel Company, Benxi, Liaoning 117000, P.R. China, Lab 1, Cancer Institute, China Medical University, Shenyang, Liaoning 110001, P.R. China, Department of Biology, Brandeis University, Waltham, MA 02453, USA
Published online on: September 18, 2014 https://doi.org/10.3892/ol.2014.2551
Pages: 2642-2648

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The mammalian target of rapamycin (mTOR)/eukaryotic translation initiation factor 4E‑binding protein 1 (4E‑BP1) pathway plays a critical role in cell growth, survival and angiogenesis, and has been demonstrated to correlate with human epidermal growth factor receptor 2 (HER2) status. Neoadjuvant chemotherapy (NAC), also known as preoperative therapy, is now well established in the treatment of inoperable locally advanced and inflammatory breast cancer. In vitro study has shown that mTOR inhibitors, together with cytotoxic agents, exhibit tumor cell killing activity. A number of non‑randomized studies in HER2‑positive trastuzumab‑resistant metastatic breast cancer have revealed the antitumor activity of mTOR inhibitors when used together with standard chemotherapy plus trastuzumab. In the present study, the expression levels of phosphorylated (p)‑mTOR and p‑4E‑BP1 were analyzed in breast cancer patients prior to and following NAC, to determine whether p‑mTOR and p‑4E‑BP1 affect the response to NAC and the subsequent survival. Formalin‑fixed, paraffin‑embedded tissues representing matched pairs of core biopsy (pre‑NAC) and surgical specimen (post‑NAC) from 83 patients with invasive ductal carcinomas were collected. Immunohistochemistry was performed to evaluate the expression of p‑mTOR and p‑4E‑BP1 using a semi‑quantitative scoring system by two pathologists. It was found that the expression of p‑mTOR and p‑4E‑BP1 was downregulated following NAC. The decrease in mTOR expression following NAC was found to positively correlate with HER2 expression and the reduction of tumor sizes. The high expression of p‑mTOR and p‑4E‑BP1 in pre‑NAC specimens was associated with poor disease‑free survival (DFS). Furthermore, the high expression of p‑mTOR in post‑NAC specimens was associated with poor DFS, regardless of whether the expression was high or low in the pre‑NAC specimens. In conclusion, NAC was found to decrease the expression levels of p‑mTOR and p‑4E‑BP1. The p‑mTOR expression post‑NAC may potentially serve as a predictor for DFS. However, further study is required to clarify the mechanism and to evaluate the predictive value of the phosphatidylinositol 3‑kinase/Akt/mTOR/4E‑BP1 pathway in NAC.

View Figures

View References

1	Ma XM and Blenis J: Molecular mechanisms of mTOR-mediated translational control. Nature Rev Mol Cell Biol. 10:307–318. 2009.
2	Zhou X, Tan M, Stone Hawthorne V, et al: Activation of the Akt/mammalian target of rapamycin/4E-BP1 pathway by ErbB2 overexpression predicts tumor progression in breast cancers. Clinical Cancer Res. 10:6779–6788. 2004.
3	Meric-Bernstam F and Gonzalez-Angulo AM: Targeting the mTOR signaling network for cancer therapy. J Clin Oncol. 27:2278–2287. 2009.
4	Faivre S, Kroemer G and Raymond E: Current development of mTOR inhibitors as anticancer agents. Nat Rev Drug Discov. 5:671–688. 2006.
5	Margariti N, Fox SB, Bottini A and Generali D: ‘Overcoming breast cancer drug resistance with mTOR inhibitors’. Could it be a myth or a real possibility in the short-term future? Breast Cancer Res Treat. 128:599–606. 2011.
6	Gingras AC, Raught B and Sonenberg N: eIF4 initiation factors: effectors of mRNA recruitment to ribosomes and regulators of translation. Annu Rev Biochem. 68:913–963. 1999.
7	Hara K, Yonezawa K, Kozlowski MT, et al: Regulation of eIF-4EBP1 phosphorylation by mTOR. J Biol Chem. 272:26457–26463. 1997.
8	von Manteuffel SR, Dennis PB, Pullen N, et al: The insulin-induced signalling pathway leading to S6 and initiation factor 4E binding protein 1 phosphorylation bifurcates at a rapamycin-sensitive point immediately upstream of p70s6k. Mol Cell Biol. 17:5426–5436. 1997.
9	Brunn GJ, Hudson CC, Sekulić A, et al: Phosphorylation of the translational repressor PHAS-I by the mammalian target of rapamycin. Science. 277:99–101. 1997.
10	Heikkinen T, Korpela T, Fagerholm R, et al: Eukaryotic translation initiation factor 4E (eIF4E) expression is associated with breast cancer tumor phenotype and predicts survival after anthracycline chemotherapy treatment. Breast Cancer Ress Treat. 141:79–88. 2013.
11	Coleman LJ, Peter MB, Teall TJ, et al: Combined analysis of eIF4E and 4E-binding protein expression predicts breast cancer survival and estimates eIF4E activity. Br J Cancer. 100:1393–1399. 2009.
12	Jefferies HB, Fumagalli S, Dennis PB, et al: Rapamycin suppresses 5′TOP mRNA translation through inhibition of p70s6k. EMBO J. 16:3693–3704. 1997.
13	Kim EK, Kim HA, Koh JS, et al: Phosphorylated S6K1 is a possible marker for endocrine therapy resistance in hormone receptor-positive breast cancer. Breast Cancer Res Treat. 126:93–99. 2011.
14	Fuksa L, Micuda S, Grim J, Ryska A and Hornychova H: Predictive biomarkers in breast cancer: their value in neoadjuvant chemotherapy. Cancer Invest. 30:663–678. 2012.
15	Mieog JS, van der Hage JA and van de Velde CJ: Neoadjuvant chemotherapy for operable breast cancer. Br J Surg. 94:1189–1200. 2007.
16	Kuerer HM, Newman LA, Smith TL, et al: Clinical course of breast cancer patients with complete pathologic primary tumor and axillary lymph node response to doxorubicin-based neoadjuvant chemotherapy. J Clin Oncol. 17:460–469. 1999.
17	Ogston KN, Miller ID, Payne S, et al: A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast. 12:320–327. 2003.
18	Thomas E, Holmes FA, Smith TL, et al: The use of alternate, non-cross-resistant adjuvant chemotherapy on the basis of pathologic response to a neoadjuvant doxorubicin-based regimen in women with operable breast cancer: long-term results from a prospective randomized trial. J Clin Oncol. 22:2294–2302. 2004.
19	Heys SD, Hutcheon AW, Sarkar TK, et al: Neoadjuvant docetaxel in breast cancer: 3-year survival results from the Aberdeen trial. Clin Breast Cancer. 3(Suppl 2): S69–S74. 2002.
20	Guertin DA and Sabatini DM: Defining the role of mTOR in cancer. Cancer Cell. 12:9–22. 2007.
21	Dillon RL, White DE and Muller WJ: The phosphatidyl inositol 3-kinase signaling network: implications for human breast cancer. Oncogene. 26:1338–1345. 2007.
22	Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast tumours. Nature. 490:61–70. 2012.
23	Banerji S, Cibulskis K, Rangel-Escareno C, et al: Sequence analysis of mutations and translocations across breast cancer subtypes. Nature. 486:405–409. 2012.
24	Saal LH, Holm K, Maurer M, et al: PIK3CA mutations correlate with hormone receptors, node metastasis, and ERBB2, and are mutually exclusive with PTEN loss in human breast carcinoma. Cancer Res. 65:2554–2559. 2005.
25	Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, et al: An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer. Cancer Res. 68:6084–6091. 2008.
26	Mondesire WH, Jian W, Zhang H, et al: Targeting mammalian target of rapamycin synergistically enhances chemotherapy-induced cytotoxicity in breast cancer cells. Clinical Cancer Res. 10:7031–7042. 2004.
27	Jerusalem G, Fasolo A, Dieras V, et al: Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat. 125:447–455. 2011.
28	Andre F, Campone M, O’Regan R, et al: Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. J Clin Oncol. 28:5110–5115. 2010.
29	Huober J, Hanusch C, Fasching PA, et al: Neoadjuvant chemotherapy of paclitaxel with or without Rad001: Results of the non-responder part of the GEPARUINTO study. In: Presented at 33rd Annual San Antonio Breast Cancer Symposium; San Antonio, TX. 2011
30	Yardley DA: Combining mTOR inhibitors with chemotherapy and other targeted therapies in advanced breast cancer: Rationale, clinical experience, and future directions. Breast Cancer (Auckl). 7:7–22. 2013.
31	Yang F and Li J: WHO classification of tumors of the breast. Zhonghua Wai Ke Za Zhi. 52:1–3. 2014.(In Chinese).
32	Chen J and Fang Y: A novel pathway regulating the mammalian target of rapamycin (mTOR) signaling. Biochemical Pharmacol. 64:1071–1077. 2002.
33	Mita MM, Mita A and Rowinsky EK: The molecular target of rapamycin (mTOR) as a therapeutic target against cancer. Cancer Biol Ther. 2(4 Suppl 1): S169–S177. 2003.
34	Hiller DJ, Chu Q, Meschonat C, et al: Predictive value of eIF4E reduction after neoadjuvant therapy in breast cancer. J Surg Res. 156:265–269. 2009.
35	Klos KS, Wyszomierski SL, Sun M, et al: ErbB2 increases vascular endothelial growth factor protein synthesis via activation of mammalian target of rapamycin/p70S6K leading to increased angiogenesis and spontaneous metastasis of human breast cancer cells. Cancer Res. 66:2028–2037. 2006.
36	Hanrahan EO, Hennessy BT and Valero V: Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials. Expert Opin Pharmacother. 6:1477–1491. 2005.